|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Benazepril#Clinical Studies]] |
| {{Benazepril}}
| |
| {{CMG}} ; {{AE}} {{AM}}
| |
| | |
| ==Clinical Studies==
| |
| | |
| ====Hypertension====
| |
| | |
| ======Adult======
| |
| | |
| In single-dose studies, Lotensin lowered [[blood pressure]] within 1 hour, with peak reductions achieved 2-4 hours after dosing. The [[antihypertensive]] effect of a single dose persisted for 24 hours. In multiple-dose studies, once-daily doses of 20-80 mg decreased seated pressure (systolic/diastolic) 24 hours after dosing by about 6-12/4-7 mmHg. The trough values represent reductions of about 50% of that seen at peak.
| |
| | |
| Four dose-response studies using once-daily dosing were conducted in 470 mild-to-moderate [[hypertensive]] patients not using diuretics. The minimal effective once-daily dose of Lotensin was 10 mg; but further falls in [[blood pressure]], especially at morning trough, were seen with higher doses in the studied dosing range (10-80 mg). In studies comparing the same daily dose of Lotensin given as a single morning dose or as a twice-daily dose, blood pressure reductions at the time of morning trough blood levels were greater with the divided regimen.
| |
| | |
| The [[antihypertensive]] effects of Lotensin were not appreciably different in patients receiving high- or low-sodium diets.
| |
| | |
| In normal human volunteers, single doses of benazepril caused an increase in [[renal blood flow]] but had no effect on [[glomerular filtration rate]].
| |
| | |
| Use of Lotensin in combination with [[thiazide diuretics]] gives a blood-pressure-lowering effect greater than that seen with either agent alone. By blocking the [[renin-angiotensin-aldosterone axis]], administration of Lotensin tends to reduce the [[potassium]] loss associated with the diuretic.
| |
| | |
| ======Pediatric======
| |
| | |
| In a clinical study of 107 pediatric patients, 7 to 16 years of age, with either [[systolic]] or [[diastolic pressure]] above the 95th percentile, patients were given 0.1 or 0.2 mg/kg then titrated up to 0.3 or 0.6 mg/kg with a maximum dose of 40 mg once daily. After four weeks of treatment, the 85 patients whose [[blood pressure]] was reduced on therapy were then randomized to either placebo or benazepril and were followed up for an additional two weeks. At the end of two weeks, [[blood pressure]] (both systolic and diastolic) in children withdrawn to placebo rose by 4 to 6 mmHg more than in children on benazepril. No dose-response was observed for the three doses.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LOTENSIN (BENAZEPRIL HYDROCHLORIDE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d954024-a191-46e3-ba71-2a7d5b0c65d5#nlm34067-9 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |